> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-47/
- Published: 2021-07-18T12:00:00.000Z
- Updated: 2026-09-14T17:06:41.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5149737

**Guide on Product-specific Bioequivalence**  
*7/16/2021 Federal Register* notice: FDA has made available a draft guidance entitled “Draft Guidance for Cilastatin Sodium; Imipenem; Relebactam.” The document provides product-specific recommendations on the bioequivalence study designs to support ANDA submissions for such products. To view the notice, click [here](https://public-inspection.federalregister.gov/2021-15170.pdf?ref=fdaweb.com).  

**Proposed Study of Medical Conference Drug Promotions**  
*7/16/2021 Federal Register* notice: FDA has submitted to OMB a proposed information collection entitled “Medical Conference Attendees’ Observations About Prescription Drug Promotion.” The study is intended to focus on understanding the landscape of healthcare provider-directed promotion of prescription drugs at medical conferences in general. More specifically, it will examine elements of pharmaceutical booths in medical conference exhibit halls and the impact on attendees’ perceptions of the drugs that are promoted at those booths. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-07-14/pdf/2021-14936.pdf?ref=fdaweb.com).  

**Stromectol Not Withdrawn Due to Safety/Efficacy**  
*7/14/2021 Federal Register* notice: FDA has determined that Merck’s Stromectol (ivermectin) tablets, 6 mg, were not withdrawn from sale for reasons of safety or effectiveness. The determination will allow FDA to approve ANDAs that reference the product if all other legal and regulatory requirements are met. The product is indicated for strongyloidiasis of the intestinal tract and onchocerciasis. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-07-14/pdf/2021-14935.pdf?ref=fdaweb.com).  

**Guide on Animal Drug Conditional Approval**  
*7/13/2021 Federal Register* notice: FDA has made available a final guidance entitled *Eligibility Criteria for Expanded Conditional Approval of New Animal Drugs*. The document notes that eligibility for conditional approval has been expanded beyond minor uses in major species and use in minor species to include certain major uses in major species. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-07-14/pdf/2021-14938.pdf?ref=fdaweb.com).  

**Info Collection on Device Labeling Regs**  
*7/13/2021 Federal Register* notice: FDA is seeking comments on an information collection extension entitled “Medical Device Labeling Regulations” (OMB Control No. 0910-0485). The collection supports implementation of medical device labeling requirements governed by section 502 of the Federal Food, Drug, and Cosmetic Act. FDA says the revision was made to include reference to agency guidance. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-07-13/pdf/2021-14768.pdf?ref=fdaweb.com).